BridgeBio Pharma, Inc. (BBIO)

Over the past six months, BridgeBio Pharma's stock has experienced significant movements. The stock reached an all-time high driven by strong Attruby sales and positive clinical results. BridgeBio announced its Q3 2025 earnings, reporting revenue that beat expectations but also a wider net loss. The CEO sold stock under a pre-arranged plan. BridgeBio presented at the J.P. Morgan Healthcare Conference, highlighting commercial progress and pipeline updates, but the stock dropped. The announcement of the PROPEL 3 trial update also contributed to stock movements.

Analysis of demand seasonality for BridgeBio Pharma's products and services is limited due to data availability. However, the broader Healthcare sector has shown positive results compared to the S&P 500 Total Return Index over the past 5 years during a specific seasonal timeframe.

BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers driven by clear genetic factors. The company's business model leverages scientific advancements to develop therapies for rare diseases and genetically driven cancers, with a pipeline of over 30 development programs. Key products include Attruby (acoramidis) for transthyretin-mediated amyloidosis, low-dose infigratinib for achondroplasia and hypochondroplasia, encaleret for autosomal dominant hypocalcemia type 1, BBP-418 for limb-girdle muscular dystrophy type 2I/R9, and BBP-812 for congenital adrenal hyperplasia.

BridgeBio Pharma is headquartered in Palo Alto, California, and operates in the US and Japan. The company has expanded its clinical and research activities across North America, Europe, and Asia, collaborating with regulatory agencies and academic centers globally. BridgeBio also has subsidiaries in the United States, the Netherlands, Germany, and the United Kingdom.

Specific information regarding BridgeBio Pharma's brand reputation is not readily available. The company emphasizes its commitment to prioritizing patient needs, maintaining scientific rigor, and swiftly delivering groundbreaking treatments.

BridgeBio Pharma has a mixed ownership structure, with institutional, insider, and retail investors. Institutional investors hold a significant percentage of the company's stock, with major holders including Vanguard Group Inc., Viking Global Investors Lp, and BlackRock, Inc. Insiders also hold a notable portion of the stock, with KKR Group Partnership LP being the largest individual shareholder. Insiders have sold more stock than they have bought in the past three months.